Malta - angielski - Medicines Authority

kern pharma, s.l. polígono industrial colón ii calle venus 72 08228, terrassa, barcelona , spain - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 850 mg - drugs used in diabetes

Malta - angielski - Medicines Authority

kern pharma, s.l. polígono industrial colón ii calle venus 72 08228, terrassa, barcelona , spain - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes

Malta - angielski - Medicines Authority

hennig arzneimittel gmbh & co kg liebigstrasse 1-2, d-65439 flörsheim am main, germany - film-coated tablet - metformin hydrochloride 1000 mg sitagliptin 50 mg - drugs used in diabetes

Malta - angielski - Medicines Authority

pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - metformin hydrochloride 850 mg sitagliptin 50 mg - drugs used in diabetes

Malta - angielski - Medicines Authority

pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - metformin hydrochloride 1000 mg sitagliptin 50 mg - drugs used in diabetes

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - metformin hydrochloride - film coated tablet - 850 milligram - metformin

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - metformin hydrochloride - film coated tablet - 500 milligram - metformin

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - metformin hydrochloride - film coated tablet - 1000 milligram - metformin

Australia - angielski - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 850 mg; vildagliptin, quantity: 50 mg - tablet, film coated - excipient ingredients: macrogol 4000; hypromellose; iron oxide yellow; magnesium stearate; titanium dioxide; hyprolose; purified talc - for patients with type 2 diabetes mellitus (t2dm):,galvumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients whose diabetes is not adequately controlled on metformin hydrochloride alone or who are already treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. treatment should not be initiated with this fixed-dose combination.,galvumet is indicated in combination with a sulfonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulfonylurea.,galvumet is indicated as add-on to insulin as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 500 mg; vildagliptin, quantity: 50 mg - tablet, film coated - excipient ingredients: hypromellose; macrogol 4000; titanium dioxide; magnesium stearate; purified talc; iron oxide yellow; iron oxide red; hyprolose - for patients with type 2 diabetes mellitus (t2dm):,galvumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients whose diabetes is not adequately controlled on metformin hydrochloride alone or who are already treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. treatment should not be initiated with this fixed-dose combination.,galvumet is indicated in combination with a sulfonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulfonylurea.,galvumet is indicated as add-on to insulin as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.